Consistently, a very recent study revealed that in hepatocellular carcinoma (HCC), SLAMF7 upregulation was observed in immunotherapy-responsive HCC tumors, with responding patients exhibiting elevated serum SLAMF7 levels. Here, SLAMF7 is linked to hepatocellular carcinoma.